Sinovac COVID-19 vaccine clinical trials
Also written CoronaVac.
How each study uses sinovac COVID-19 vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2021 (20)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 20 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 16
Sinovac Research and Development Co., Ltd. (6) · The University of Hong Kong (2) · Butantan Institute (2) · Sinovac Life Sciences Co., Ltd. (2) · D'Or Institute for Research and Education (2) · Jiangsu Province Centers for Disease Control and Prevention (1) · Health Institutes of Turkey (1) · University of Sao Paulo General Hospital (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses sinovac COVID-19 vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)CompletedPhase 4The University of Hong KongNCT05057169Written as CoronaVacHow we know
- Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 VaccineCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT05303584Written as CoronaVacHow we know
- Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and AboveCompletedPhase 3Sinovac Research and Development Co., Ltd.NCT05381350Written as COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)How we know
- Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)CompletedPhase 3Health Institutes of TurkeyNCT04582344Written as CoronaVacHow we know
- COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDSCompletedPhase 4University of Sao Paulo General HospitalNCT04754698Written as CoronaVacHow we know
- Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare ProfessionalsCompletedPhase 3Butantan InstituteNCT04456595Written as Adsorbed COVID-19 (inactivated) VaccineHow we know
- An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) VaccineCompletedPhase 4Butantan InstituteNCT04747821Written as Adsorbed COVID-19 (Inactivated) VaccineHow we know
- Covid-19 Vaccination in Adolescents and ChildrenActive, not recruitingPhase 2The University of Hong KongNCT04800133Written as CoronaVacHow we know
- Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 YearsActive, not recruitingPhase 4Sinovac Research and Development Co., Ltd.NCT05112913Written as Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2How we know
- Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 YearsCompletedPhase 3Sinovac Research and Development Co., Ltd.NCT05137418Written as COVID-19 Vaccine,InactivatedHow we know
- Antibody Response to COVID-19 Vaccines in Liver Disease PatientsCompletedPhase 4Humanity & Health Medical Group LimitedNCT04775069Written as CoronaVacHow we know
- Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in AdultsCompletedPhase 4Sinovac Research and Development Co., Ltd.NCT04911790Written as Experimental GroupHow we know
- Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and AdolescentsCompletedPhase 4Sinovac Life Sciences Co., Ltd.NCT04992208Written as Experimental GroupHow we know
- Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and AdolescentsCompletedPhase 2Sinovac Life Sciences Co., Ltd.NCT04884685Written as SARS-CoV-2 Inactivated VaccineHow we know
- Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in AdultsCompletedPhase 3Pontificia Universidad Catolica de ChileNCT04651790Written as SARS-CoV-2 inactivated vaccineHow we know
- Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 VaccinesCompletedPhase 3Institut Pasteur de TunisNCT05668065Written as CoronaVac/CoronaVacHow we know
- SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer PatientsCompletedNot applicableNational Cancer Institute, ThailandNCT05313074Written as CoronaVac vaccineHow we know
- Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy AdultsCompletedPhase 4Sinovac Research and Development Co., Ltd.NCT04894227Written as Inactivated SARS-CoV-2 Vaccine (Vero cell)How we know
- Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant RecipientsStatus unknownPhase 4Hospital do Rim e HipertensãoNCT04801667Written as CoronavacHow we know
- Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19Status unknownPhase 4Sinovac Biotech Co., LtdNCT05079217Written as High-dosage SARS-CoV-2 vaccineHow we know
See all 25 studies that test sinovac COVID-19 vaccine →
As the comparator · 15 — what is tested is compared with sinovac COVID-19 vaccine
- Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy AdolescentCompletedPhase 2Health Institutes of TurkeyNCT05230940Written as CoronaVacHow we know
- Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine BoosterCompletedPhase 1Argorna Pharmaceuticals Co., LTDNCT05897190Written as CoronaVac®How we know
- Phase 3 Booster Vaccination Against COVID-19CompletedPhase 3Health Institutes of TurkeyNCT05077176Written as CoronaVacHow we know
- Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac VaccineCompletedPhase 3Health Institutes of TurkeyNCT04942405Written as CoronaVacHow we know
- Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in ChileCompletedPhase 2Pontificia Universidad Catolica de ChileNCT05593042Written as CoronaVac®How we know
- Booster Vaccination Against COVID-19CompletedPhase 2Health Institutes of TurkeyNCT04979949Written as CoronaVacHow we know
- Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in AdultsCompletedPhase 3Clover Biopharmaceuticals AUS Pty LtdNCT05188677Written as CoronaVac VaccineHow we know
- The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001Active, not recruitingEarly Phase 1Guangzhou Patronus Biotech Co., Ltd.NCT05928455Written as CoronaVacHow we know
- Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018CompletedPhase 1PT Bio FarmaNCT05228613Written as SARS-CoV-2 inactivated vaccineHow we know
- Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in IslamabadStatus unknownPhase 3AIM Vaccine Co., Ltd.NCT05428592Written as CoronaVac®How we know
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy PeopleStatus unknownPhase 3Sinocelltech Ltd.NCT05683561Written as CoronaVacHow we know
- Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351Status unknownEarly Phase 1Livzon Pharmaceutical Group Inc.NCT05583357Written as CoronaVacHow we know
- Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly AdultsCompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04952727Written as Inactive SARS-CoV-2 vaccine (Vero cell)How we know
- Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant VaccineCompletedPhase 1PT Bio FarmaNCT05067894Written as SARS-CoV-2 Inactivated VaccineHow we know
- Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)CompletedPhase 4Jiangsu Province Centers for Disease Control and PreventionNCT04892459Written as Inactive SARS-CoV-2 vaccine (Vero cell)How we know
Codes
What other systems call sinovac COVID-19 vaccine · ClinicalTrials.gg INT001828
- MeSH (NLM) C000722216sinovac COVID-19 vaccineOne source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722216 | sinovac COVID-19 vaccine | One source NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.